SEC Form 4 · accession 0001209191-17-006791
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul C Grint
Officer — President & CEO · Director
Period of report
Jan 30, 2017
Accepted (ET)
Feb 1, 2017 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.35 | Jan 30, 2017 | A | 130,000 | A | Jan 30, 2017 | Feb 3, 2026 | Common Stock | 130,000 | 130,000 | D |
Explanation of responses
- F1On February 4, 2016, the reporting person was granted an option to purchase 130,000 shares of common stock. The option vests only upon achievement of a performance-based milestone. The performance criteria were met on January 30, 2017, resulting in vesting of the option. Upon achievement of the milestone, fifty percent of the shares immediately vest with the remaining shares vesting over the 24 month period following the vesting commencement date, subject to the reporting person's continuous service to Regulus.